Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 16Doxorubicin 13pembrolizumab 11Temozolomide 11X-Rays 10Radiation 10atezolizumab 8Radiotherapy 8Irinotecan 8Phantoms, Imaging 7Nivolumab 7fludarabine 6Vincristine 6Immunoglobulin G 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5cemiplimab 5cabozantinib 5Sirolimus 5Ifosfamide 5Gemcitabine 5Disulfides 5palbociclib 4olaparib 4fludarabine phosphate 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epothilones × Sarcoma × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡